10-Q: CEL-SCI Reports Q2 2024 Results, Advances Multikine Regulatory Strategy

CEL-SCI Corporation reported its financial results for the quarter ended March 31, 2024, and provided an update on its regulatory strategy for Multikine.

Summary

• CEL-SCI Corporation, a clinical-stage biotechnology company, released its financial results for the quarter ended March 31, 2024.
• The company reported a net loss of $7.2 million for the three months ended March 31, 2024, and a net loss of $13.9 million for the six months ended March 31, 2024.
• Research and development expenses decreased by 24% for the three months ended March 31, 2024, and 22% for the six months ended March 31, 2024, compared to the same periods in 2023.
• General and administrative expenses increased by 17% for the three months ended March 31, 2024, and 5% for the six months ended March 31, 2024, compared to the same periods in 2023.
• The company's cash and cash equivalents increased to $5.3 million as of March 31, 2024, compared to $4.1 million as of September 30, 2023.
• CEL-SCI is focused on developing Multikine, an investigational immunotherapy for head and neck cancers, and LEAPS technology for rheumatoid arthritis.
• The company is in discussions with regulators about a confirmatory trial for Multikine, focusing on patients who showed the best response in the previous Phase III study.
• The FDA has indicated that CEL-SCI may move forward with a confirmatory registration study of Multikine in newly diagnosed advanced primary head and neck cancer patients with no lymph node involvement and low PD-L1 tumor expression.
• The confirmatory study will enroll 212 patients and is designed to confirm the survival benefit observed in the Phase 3 study.

Sentiment

Score: 7

Explanation: The document presents a positive outlook for Multikine's regulatory path and potential efficacy, but the company's financial situation and dependence on future capital raises temper the overall sentiment. The strong survival data is a major positive, but the going concern warning and need for additional funding are significant risks.

Positives

• The company's cash position improved, with cash and cash equivalents increasing to $5.3 million.
• The FDA has agreed to a smaller, 212-person confirmatory study for Multikine, which could accelerate the path to potential approval.
• The Phase III trial data showed a significant survival benefit for the target population treated with Multikine, with a 73% 5-year survival rate compared to 45% in the control group.
• The hazard ratio of 0.35 in the target population indicates a significantly reduced risk of death for patients treated with Multikine.
• Research and development expenses decreased, indicating a potential focus on efficiency.

Negatives

• The company continues to incur net losses, with a net loss of $7.2 million for the three months ended March 31, 2024, and $13.9 million for the six months ended March 31, 2024.
• General and administrative expenses increased, which could indicate rising operational costs.
• The company has a going concern warning due to recurring losses and future liquidity needs.
• The company is dependent on raising additional capital to continue operations.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring losses and future liquidity needs.
• The company is dependent on raising additional capital, and there is no guarantee that it will be able to do so on acceptable terms.
• The company's product candidates have not been approved for sale, and there is no guarantee that they will receive regulatory approval.
• The company's clinical trials and research programs are dependent on the amount of capital available and regulatory approvals.
• The company's disclosure controls and procedures were not effective as of March 31, 2024, due to material weaknesses.

Future Outlook

CEL-SCI plans to seek regulatory approval for Multikine based on the Phase III data and the confirmatory study, focusing on the target population with no lymph node involvement and low PD-L1 tumor expression. The company will continue to develop Multikine and LEAPS technology and will likely need to raise additional capital to fund these activities.

Management Comments

• CEL-SCI believes that the Phase III clinical trial demonstrated that Multikine caused tumors to reduce in size and/or caused the disease to downstage within just a few weeks of treatment before surgery.
• CEL-SCI is in discussions with regulators about the design of a confirmatory trial focused on the patients selected as the best responding patients in the prior study.
• The FDA agreed to a 212-person confirmatory Registration Study based on the strength of the safety and survival benefit data in the selected target population from the prior 928-person Phase 3 study.
• CEL-SCI believes that its de-risked value proposition for investors presents a unique opportunity to invest in a Phase 3 oncology company with a large body of data demonstrating not only tumor responses, but also long-term survival, in the target patient population.

Industry Context

The report highlights the growing market for cancer immunotherapies and positions Multikine as a potential player in this market. The focus on a specific patient population with low PD-L1 expression differentiates Multikine from other immunotherapies like checkpoint inhibitors, which are more effective in patients with high PD-L1 expression. The company is seeking to leverage conditional approval pathways, which are designed for situations where there is a strong clinical benefit for patients but the target population has not been fully tested prospectively.

Comparison to Industry Standards

• The report mentions that the global cancer immunotherapy market is expected to reach USD $196.45 billion by 2030, indicating a significant market opportunity for CEL-SCI.
• The company's Phase III trial results showed a 73% 5-year survival rate in the target population treated with Multikine, compared to 45% in the control group, which is a significant improvement over the standard of care.
• The hazard ratio of 0.35 in the Multikine target population is also a strong indicator of efficacy, as it suggests a significantly lower risk of death compared to the control group.
• The report notes that checkpoint inhibitors like Keytruda and Opdivo work best on tumors with high PD-L1 expression, while Multikine works best in tumors with low PD-L1 expression, suggesting a different niche for Multikine in the immunotherapy landscape.
• The company's approach of using Multikine as a first-line treatment before surgery is also different from many other immunotherapies, which are typically given after surgery or when surgery is not an option.

Related Party Transactions

• On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024. The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend. The Series RR warrants are held by Geert Kersten, Patricia Prichep (current officers of the Company) and the de Clara Trust, of which the Company's CEO, Geert Kersten, is a beneficiary.

Stakeholder Impact

• Shareholders may be impacted by the company's need to raise additional capital, which could dilute their ownership.
• Employees may be impacted by the company's financial situation and the potential for future layoffs or restructuring.
• Patients with head and neck cancer may benefit from the potential approval of Multikine, which has shown promising survival benefits in clinical trials.
• Creditors may be impacted by the company's financial situation and its ability to repay its debts.

Next Steps

• CEL-SCI will move forward with a confirmatory registration study of Multikine in newly diagnosed advanced primary head and neck cancer patients with no lymph node involvement and low PD-L1 tumor expression.
• The company will seek regulatory approval for Multikine based on the Phase III data and the confirmatory study.
• The company will continue to develop Multikine and LEAPS technology.

Key Dates

Keywords

Multikine, Immunotherapy, Head and Neck Cancer, Clinical Trial, FDA, Regulatory Approval, Phase III, Survival Benefit, PD-L1, Biotechnology